Circulating biomarkers for the diagnosis and prognosis of heart failure

Current Medicinal Chemistry

Volumn 16, Issue 29, 2009, Pages 3828-3840

  Tousoulis, D ^a   Kampoli, A M ^a   Siasos, G ^a   Stefanadi, E ^a   Antoniades, C ^a   Papavassiliou, A G ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biomarkers; Diagnosis; Heart failure; Prognosis

Indexed keywords

ADIPOCYTOKINE; ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARDIAC TROPONIN I; CARDIAC TROPONIN T; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; CREATINE KINASE MB; CYCLOOXYGENASE 2; CYTOKINE; ENDOTHELIN; FATTY ACID BINDING PROTEIN; HEART TYPE FATTY ACID BINDING PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; MALONALDEHYDE; METALLOPROTEINASE; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE; PROTEIN ST2; REGULATOR PROTEIN; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HEART FAILURE; HUMAN; LIPID OXIDATION; MUSCLE NECROSIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HEART FAILURE; HUMANS; INFLAMMATION; NATRIURETIC PEPTIDE, BRAIN;

EID: 70450159686     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789178000     Document Type: Review

References (71)

1. Apple, F.S.; Wu, A.H.; Mair, J.; Ravkilde, J.; Panteghini, M.; Tate, J.; Pagani, F.; Christenson, R.H.; Mockel, M.; Danne, O.; Jaffe, A.S. Committee on standardization of markers of cardiac damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem., 2005, 51, 810.
2. Kinugawa, S.; Tsutsui, H.; Hayashidani, S. Ide, T.; Suematsu, N.; Satoh, S.; Utsumi, H.; Takeshita, A. Treatment with dimethylthiourea prevents left ventricular remodelling and failure after experimental myocardial infarction in mice: Role of oxidative stress. Circ. Res., 2000, 87, 392. (Pubitemid 30688989)
3. Byrne, J.A.; Grieve, D.J.; Cave, A.C.; Shah, A.M. Oxidative stress and heart failure. Arch. Mal. Coeur. Vaiss., 2003, 96, 214.
4. Iwanaga, Y.; Nishi, I.; Furuichi, S.; Noguchi, T.; Sase, K.; Kihara, Y.; Goto, Y.; Nonogi. H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J. Am. Coll. Cardiol., 2006, 47,742. (Pubitemid 43243094)
5. Davis, M.; Espiner, E.; Richards, G.; Billings, J.; Town, I.; Neill, A.; Drennan, C.; Richards, M.; Turner, J.; Yandle, T. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet, 1994, 343, 440. (Pubitemid 24059585)
6. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Conlon, C.; Patle, A.; Donelly, S.M.; McDonald, K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation, 2007,115, 888. (Pubitemid 46294729)
7. Januzzi, J.L.; van Kimmenade, R.; Lainchbury, J.; Bayes-Genis, A.; Ordonez-Llanos, J.; Jourdain, P.; Jondeau, G.; Funck, F.; Gueffet, P.; Le Helloco, A.; Donal, E.; Aupetit, J.F.; Aumont, M.C.; Galinier, M.; Eicher, J.C.; Cohen-Solal, A.; Juilliere, Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol., 2007, 49, 1733. (Pubitemid 46589928)
8. Stanek, B.; Frey, B.; Hulsmann, M.; Berger, R.; Sturm, B.; Strametz-Juranek, J.; Bergler-Klein, J.; Moser, P.; Bojic, A.; Hartter, E.; Pacher, R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol., 2001, 38, 436. (Pubitemid 32721772)
9. Doust, J.A.; Pietrzak, E.; Dobson, A.; Glasziou, P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ, 2005, 330, 625. (Pubitemid 40444756)
10. Fonarow, G.C. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. Rev. Cardiovasc. Med., 2003, 4, 20.
11. Januzzi, J.L. Jr.; Peacock, W.F.; Maisel, A.S.; Chae, C.U.; Jesse, R.L.; Baggish, A.L.; O'Donoghue, M.; Sakhuja, R.; Chen, A.A.; Van Kimmenade, R.R.; Lewandrowski, K.B.; Lloyd-Jones, D.M.; Wu, A.H. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study. J. Am. Coll. Cardiol., 2007, 50, 607.
12. Januzzi, J.L.; van Kimmenade, R.; Lainchbury. J.; Bayes-Genis, A.; Santalo-Bel, M.; Pinto, Y.M.; Richards, M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur. Heart J., 2006, 27, 330. (Pubitemid 43100029)
13. Troughton, R.W.; Frampton, C.M.; Yandle, T.G.; Espiner, E.A.; Nicholls, M.G.; Richards, A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, 2000, 355, 1126.
14. Hartmann, F.; Packer, M.; Coats, A.J.; Fowler, M.B.; Krum, H.; Mohacsi, P.; Rouleau, J.L.; Tendera, M.; Castaigne, A.; Anker, S.D.; Amann-Zalan, I.; Hoersch, S.; Katus, H.A. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation, 2004, 110, 1780.
15. Tschöpe, C.; Kasner, M.; Westermann, D.; Gaub, R.; Poller, W.C.; Schultheiss, H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur. Heart J., 2005, 21, 2277. (Pubitemid 41541392)
16. Gottdiener, J.S.; Arnold, A.M.; Aurigemma, G.P.; Polak, J.F.; Tracy, R.P.; Kitzman, D.W.; Gardin, J.M.; Rutledgem J.E.; Boineaum R.C. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol., 2000, 35, 1628.
17. Vasan, R.S.; Sullivan, L.M.; Roubenoff, R.; Dinarello, C.A.; Harris, T.; Benjamin, E.J.; Sawyer, D.B.; Levy, D.; Wilson, P.W.; D'Agostino, R.B.; Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation, 2003, 107, 1486.
18. Cesari, M.; Penninx, B.W.; Newman, A.B.; Kritchevsky, S.B.; Nicklas, B.J.; Sutton-Tyrrell, K.; Rubin, S.M.; Ding, J.; Simonsick, E.M.; Harris, T.B.; Pahor, M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation, 2003, 108, 2317. (Pubitemid 37413536)
19. Arroyo-Espliquero, R.; Avanzas, P.; Quiles, J.; Kaski, J.C. Creactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina. Atherosclerosis, 2009, 205, 319.
20. Zairis, M.N.; Tsiaousis, G.Z.; Georgilas, A.T.; Makrygiannis, S.S.; Adamopoulou, E.N.; Handanis, S.M.; Batika, P.C.; Prekates, A.A.; Velissaris, D.; Kouris, N.T.; Mytas, D.Z.; Babalis, D.K.; Karidis, K.S.; Foussas, S.G. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int. J. Cardiol., 2009 [ahead of print].
21. Tang, W.H. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am. J. Cardiol., 2008, 101, 370.
22. Wijeysundera, H.C.; Hansen, M.S.; Stanton, E.; Cropp, A.S.; Hall, C.; Dhalla, N.S.; Ghali, J.; Rouleau, J.L. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am. Heart J., 2003, 146, 291.
23. Deswal, A.; Petersen, N.J.; Feldman, A.M.; Young, J.B.; White, B.G.; Mann, D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation, 2001, 103, 2055.
24. Kapadia, S.R.; Yakoob, K.; Nader, S.; Thomas, J.D.; Mann, D.L.; Griffin, B.P. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J. Am. Coll. Cardiol., 2000, 36, 208.
25. Tentolouris, C.; Tousoulis, D.; Antoniades, C.; Bosinakou, E.; Kotsopoulou, M.; Trikas, A.; Toutouzas, P.; Stefanadis, C. Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int. J. Cardiol., 2004, 94, 301. (Pubitemid 38490677)
26. Birks, E.J.; Owen, V.J.; Burton, P.B.; Bishop, A.E.; Banner, N.R.; Khaghani, A.; Polak, J.M.; Yacoub, M.H. Tumor necrosis factoralpha is expressed in donor heart and predicts right ventricular failure after human heart transplantation. Circulation, 2000, 102, 326.
27. Tsutamoto, T.; Hisanaga, T.; Wada, A.; Maeda, K.; Ohnishi, M.; Fukai, D.; Mabuchi, N.; Sawaki, M.; Kinoshita, M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol., 1998, 31, 391. (Pubitemid 28153460)
28. Wollert, K.C.; Drexler, H. The role of interleukin-6 in the failing heart. Heart Fail. Rev., 2001, 6, 95.
29. Aukrust, P.; Ueland, T.; Muller, F.; Andreassen, A.K.; Nordoy, I.; Aas, H.; Kjekshus, J.; Simonsen, S.; Froland, S.S.; Gullestad, L. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation, 1998,97,1136. (Pubitemid 28152886)
30. Damas, J.K.; Gullestad, L.; Ueland, T.; Solum, N.O.; Simonsen, S.; Froland, S.S.; Aukrust, P. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc. Res., 2000, 45, 428.
31. Tanaka, T.; Tsutamoto, T.; Nishiyama, K.; Sakai, H.; Fuji, M.; Yamamoto, T.; Horie, M. Impact of oxidative stress on plasma adiponectin in patients with chronic heart failure. Circ. J., 2008, 72, 563. (Pubitemid 351679407)
32. Haugen, E.; Furukaya, Y.; Isic, A.; Fu, M. Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study. Int. J. Cardiol., 2008,125,216.
33. Takano, H.; Obata, J.E.; Kodama, Y.; Kitta, Y.; Nakamura, T.; Mende, A.; Kawabata, K.W.; Saito, Y.; Fujioka, D.; Kobayashi, T.; Yano, T.; Sano, K.; Kugiyama, K. Adiponectin is released from the heart in patients with heart failure. Int. J. Cardiol., 2009, 132, 221.
34. Tamura, T.; Furukawa, Y.; Taniguchi, R.; Sato, Y.; Ono, K.; Horiuchi, H.; Nakagawa, Y.; Kita, T.; Kimura, T. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ. J., 2007, 71, 623. (Pubitemid 46683348)
35. Wong, S.C.; Fukuchi, M.; Melnyk, P.; Rodger, I.; Giaid, A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation, 1998, 98, 100. (Pubitemid 28317888)
36. Kelly, D.; Cockerill, G.; Thompson, M.; Khan, S.; Samani, N.; Squire, I. Plasma metalloproteinase-9 and left ventriclar remodelling after acute myocardial infarction in man: a prospective cohort study. Eur. Heart J., 2007, 28, 711. (Pubitemid 46439245)
37. Horwich, T.B.; Patel, J.; MacLellan, W.R.; Fonarow, G.C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation, 2003,108,833.
38. Perna, E.R.; Macin, S.M.; Cimbaro, Canella, J.P.; Alvarenga, P.M.; Ríos, N.G.; Pantich, R.; Augier, N.; Farías, E.F.; Jantus, E.; Brizuela, M.; Medina, F. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. Int. J. Cardiol., 2005, 99, 253. (Pubitemid 40320798)
39. Fonarow, G.C.; Peacock, W.F.; Phillips, C.O.; Givertz, M.M.; Lopatin, M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol., 2007, 49, 1943. (Pubitemid 46694287)
40. Taniguchi, R. Measurements of baseline and follow-up concentrations of cardiac troponin T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels, 2006, 6, 344.
41. Nishio, Y. Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ. J., 2007, 71, 631. (Pubitemid 46683349)
42. Sundström, J. Cardiac troponin-I and risk of heart failure: a community- based cohort study. Eur. Heart J., 2009, 30, 773.
43. Ilva, T. Clinical significance of cardiac troponins I and T in acute heart failure. Eur. J. Heart Fail., 2008, 10, 772.
44. Goto, T. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart, 2003, 89, 1303. (Pubitemid 37311090)
45. Yilmaz, A. Clinical importance of elevated CK-MB and troponin I levels in congestive heart failure. Adv. Ther., 2006, 23, 1060. (Pubitemid 46341063)
46. Sugiura, T. Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J. Card. Fail., 2005, 11, 504. (Pubitemid 41399889)
47. Ng, L.L.; Pathik, B.; Loke, I.W.; Squire, I.B.; Davies, J.E. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am. Heart J., 2006, 152, 94.
48. Tousoulis, D.; Antoniades, C.; Stefanadis, C. Assessing inflammatory status in cardiovascular disease. Heart, 2007, 93, 1001. (Pubitemid 47122060)
49. Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Increased plasma levels of adrenomedullin in patients with heart failure. J. Am. Coll. Cardiol., 1995, 26, 1424.
50. Yu, C.M.; Cheung, B.M.; Leung, R.; Wang, Q.; Lai, W.H.; Lau, C.P. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart, 2001, 86, 155.
51. Richards, A.M.; Doughty, R.; Nicholls, M.G.; MacMahon, S.; Sharpe, N.; Murphy, J.; Espiner, E.A.; Frampton, C.; Yandle, T.G. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J. Am. Coll. Cardiol., 2001, 37, 1781.
52. Randa. Abdel. Kader. M, Grace, B.D.; Badawi, N.E. Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies. Ital. J. Biochem., 2007, 56, 18.
53. Morales, M.A.; Del Ry, S.; Startari, U.; Maltinti, M.; Prontera, C.; Emdin, M.; Gianessi, D. Plasma adrenomedullin relation with Doppler-derived dP/dt in patients with congestive heart failure. Clin. Cardiol., 2006,29,126.
54. Nonaka-Sarukawa, M.; Yamamoto, K.; Aoki, H.; Takano, H.; Katsuki, T.; Ikeda, U.; Shimada K. Increased urinary 15-F2-tisoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart, 2003, 89, 871. (Pubitemid 36920809)
55. Polidori, M.C.; Pratico, D.; Savino, K.; Rokach, J.; Stahl, W.; Mecocci, P. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J. Card. Fail., 2004, 10, 334. (Pubitemid 39092686)
56. Keith, M.; Geranmayegan, A.; Sole, M.J.; Kurian, R.; Robinson, A.; Omran, A.S.; Jeejeebhoy, K.N. Increased oxidative stress in patients with congestive heart failure. J. Am. Coll. Cardiol., 1998, 31, 1352.
57. Nagatomo, Y.; Yoshikawa, T.; Kohno, T.; Yoshizawa, A.; Anzai, T.; Meguro, T.; Satoh, T.; Ogawa, S. Effects of beta-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J. Card. Fail., 2007, 13, 365. (Pubitemid 46977792)
58. McMurray, J.; Chopra, M.; Abdullah, I.; Smith, W.E.; Dargie, H.J. Evidence of oxidative stress in chronic heart failure in humans. Eur. Heart J., 1993, 14, 1493.
59. Belch, J.J.; Bridges, A.B.; Scott, N.; Chopra, M. Oxygen free radicals and congestive heart failure. Br. Heart J., 1991, 65, 245.
60. Nishiyama, Y. Ikeda, H.; Haramaki, N.; Yoshida, N.; Imaizumi, T. Oxidative stress is related to exercise intolerance in patients with heart failure. Am. Heart J., 1998, 135, 115. (Pubitemid 28073067)
61. Mueller, T.; Dieplinger, B.; Gegenhuber, A.; Poelz, W.; Pacher, R.; Haltmeyer, M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem., 2008, 54, 752.
62. Matsumori, A.; Horii, T.; Nakano, T.; Isomura, T.; Suma, H. Free immunoglobulin light-chains as a new biomarker of heart failure. 9th Annual Scientific Meeting, Heart Failure Society of America 9.18-21, Boca Raton, Florid, USA.
63. Koitabashi, N.; Arai, M.; Niwano, K.; Watanabe, A.; Endoh, M.; Suguta, M.; Yokoyama, T.; Tada, H.; Toyama, T.; Adachi, H.; Naito, S.; Oshima, S.; Nishida, T.; Kubota, S.; Takigawa, M.; Kurabayashi, M. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur. J. Heart Fail., 2008, 10, 373.
64. Parker, J.D.; Thiessen, J.J. Increased endothelin-1 production in patients with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol., 2004, 286, 1141.
65. Tousoulis, D.; Charakida, M.; Stefanadis, D. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int. J. Cardiol., 2005, 100, 347.
66. Yancy, C.W.; Saltzberg, M.T.; Berkowitz, R.L.; Bertolet, B.; Vijayaraghavan, K.; Burnham, K.; Oren, R.M.; Walker, K.; Horton, D.P.; Silver, M.A. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am. J. Cardiol., 2004, 94, 595.
67. Duckelmann, C.; Mittermayer, F.; Haider, D.G.; Altenberger, J.; Eichinger, J.; Woltz, M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2037.
68. Niizeki, T. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J. Card. Fail., 2007, 13, 120. (Pubitemid 46467389)
69. Setsuta, K. Elevated levels of both cardiomyocyte membrane and myofibril damage markers predict adverse outcomes in patients with chronic heart failure. Circ. J., 2008, 72, 569. (Pubitemid 351679408)
70. Mazovets, O.L. Heart fatty acid binding protein in patients hospitalized because of worsening heart failure. Relation to prognosis of death. Kardiologiia, 2008, 48, 24.
71. Maisel, A.S.; Krishnaswamy, P.; Nowak, R.M.; McCord, J.; Hollander, J.E.; Duc, P.; Omland, T.; Storrow, A.B.; Abraham, W.T.; Wu, A.H.; Clopton, P.; Steg, P.G.; Westheim, A.; Knudsen, C.W.; Perez, A.; Kazanegra, R.; Herrmann, H.C.; McCullough, P.A. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med., 2002, 347, 161.